Interestingly, ITGAV expression was lower in plasma from patients with cancer compared with patients with benign tumors in our study, in line with the findings of Skubitz et al. who in their recent study on 92 biomarkers (Olink’s Oncology II panel) reported lower levels of ITGAV in serum from ovarian cancer patients compared to healthy women [34]. The gene discussed is ITGAV; the disease is benign neoplasm.